Use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products

Current effective version

PDF iconAdopted guideline

Reference numberEMA/CHMP/37646/2009
Effective from01/08/2012
KeywordsPharmacogenetics, pharmacokinetics, clinical development
DescriptionThis document clarifies the requirements related to the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products. It applies predominantly to small molecule drugs as genetic effects on the pharmacokinetics of biological drugs today are much less understood.

Document history

First version

Current version

PDF iconAdopted guideline

PDF iconDraft guideline

PDF iconConcept paper

In operation: 01/08/2012–present

Published: 06/05/2010

Published: 23/04/2009

Related content

How useful was this page?

Add your rating